Subsequent Events	12 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 15. Subsequent Events. The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of consolidated financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. TYME-88-PANC (third-line Metastatic Pancreatic Cancer) In June 2021, following a comprehensive strategic review, the Company announced that it has decided to stop enrollment of the TYME-88-PANC (third-line Metastatic Pancreatic Cancer) trial, and begin the process of closing down the trial. As previously disclosed, the COVID-19 pandemic significantly impacted enrollment of this trial such that it appears it is likely to complete enrollment in a similar timeline to the second-line Precision Promise pancreatic cancer trial. There has also been a significantly higher than expected dropout of patients randomized to the chemotherapy control arm, which could potentially impact the interpretative and regulatory utility of the data. Patients currently on therapy will be allowed to continue treatment until progression or unacceptable toxicity. The estimated costs to close the trial are $2.0 million to $3.0 million and are expected to extend into fiscal year 2023.

Subsequent Events

12 Months Ended

Mar. 31, 2021

Note 15. Subsequent Events.

The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of consolidated financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.

TYME-88-PANC (third-line Metastatic Pancreatic Cancer)

In June 2021, following a comprehensive strategic review, the Company announced that it has decided to stop enrollment of the TYME-88-PANC (third-line Metastatic Pancreatic Cancer) trial, and begin the process of closing down the trial. As previously disclosed, the COVID-19 pandemic significantly impacted enrollment of this trial such that it appears it is likely to complete enrollment in a similar timeline to the second-line Precision Promise pancreatic cancer trial. There has also been a significantly higher than expected dropout of patients randomized to the chemotherapy control arm, which could potentially impact the interpretative and regulatory utility of the data. Patients currently on therapy will be allowed to continue treatment until progression or unacceptable toxicity. The estimated costs to close the trial are $2.0 million to $3.0 million and are expected to extend into fiscal year 2023.